JP2008540445A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008540445A5 JP2008540445A5 JP2008510224A JP2008510224A JP2008540445A5 JP 2008540445 A5 JP2008540445 A5 JP 2008540445A5 JP 2008510224 A JP2008510224 A JP 2008510224A JP 2008510224 A JP2008510224 A JP 2008510224A JP 2008540445 A5 JP2008540445 A5 JP 2008540445A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- site
- aav vector
- aav2
- aav
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 37
- 239000013607 AAV vector Substances 0.000 claims 17
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims 10
- 241001655883 Adeno-associated virus - 1 Species 0.000 claims 6
- 210000003169 central nervous system Anatomy 0.000 claims 6
- 108090000604 Hydrolases Proteins 0.000 claims 4
- 102000004157 Hydrolases Human genes 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 4
- 230000002132 lysosomal effect Effects 0.000 claims 4
- 102000005593 Endopeptidases Human genes 0.000 claims 3
- 108010059378 Endopeptidases Proteins 0.000 claims 3
- 210000004556 brain Anatomy 0.000 claims 3
- 210000000234 capsid Anatomy 0.000 claims 3
- 210000001638 cerebellum Anatomy 0.000 claims 3
- 239000002184 metal Substances 0.000 claims 3
- 241000202702 Adeno-associated virus - 3 Species 0.000 claims 2
- 241000580270 Adeno-associated virus - 4 Species 0.000 claims 2
- 241001634120 Adeno-associated virus - 5 Species 0.000 claims 2
- 241000972680 Adeno-associated virus - 6 Species 0.000 claims 2
- 241001164823 Adeno-associated virus - 7 Species 0.000 claims 2
- 241001164825 Adeno-associated virus - 8 Species 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000015439 Lysosomal storage disease Diseases 0.000 claims 2
- 210000003591 cerebellar nuclei Anatomy 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 210000001320 hippocampus Anatomy 0.000 claims 2
- 210000001577 neostriatum Anatomy 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 210000000278 spinal cord Anatomy 0.000 claims 2
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 208000035343 Infantile neurovisceral acid sphingomyelinase deficiency Diseases 0.000 claims 1
- 102000003729 Neprilysin Human genes 0.000 claims 1
- 108090000028 Neprilysin Proteins 0.000 claims 1
- 201000000794 Niemann-Pick disease type A Diseases 0.000 claims 1
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 claims 1
- 208000007824 Type A Niemann-Pick Disease Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 102000010126 acid sphingomyelin phosphodiesterase activity proteins Human genes 0.000 claims 1
- 210000000133 brain stem Anatomy 0.000 claims 1
- 210000003710 cerebral cortex Anatomy 0.000 claims 1
- 210000001947 dentate gyrus Anatomy 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 210000001353 entorhinal cortex Anatomy 0.000 claims 1
- 210000001652 frontal lobe Anatomy 0.000 claims 1
- 210000003016 hypothalamus Anatomy 0.000 claims 1
- 210000001259 mesencephalon Anatomy 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 210000000869 occipital lobe Anatomy 0.000 claims 1
- 108010032563 oligopeptidase Proteins 0.000 claims 1
- 210000001152 parietal lobe Anatomy 0.000 claims 1
- BULVZWIRKLYCBC-UHFFFAOYSA-N phorate Chemical compound CCOP(=S)(OCC)SCSCC BULVZWIRKLYCBC-UHFFFAOYSA-N 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 210000002975 pon Anatomy 0.000 claims 1
- 210000003523 substantia nigra Anatomy 0.000 claims 1
- 210000003478 temporal lobe Anatomy 0.000 claims 1
- 210000001103 thalamus Anatomy 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67705705P | 2005-05-02 | 2005-05-02 | |
| US60/677,057 | 2005-05-02 | ||
| US68580805P | 2005-05-31 | 2005-05-31 | |
| US60/685,808 | 2005-05-31 | ||
| PCT/US2006/017242 WO2006119458A1 (en) | 2005-05-02 | 2006-05-02 | Gene therapy for neurometabolic disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013201138A Division JP2014037418A (ja) | 2005-05-02 | 2013-09-27 | 神経代謝性疾患のための遺伝子治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008540445A JP2008540445A (ja) | 2008-11-20 |
| JP2008540445A5 true JP2008540445A5 (OSRAM) | 2009-07-09 |
| JP5829372B2 JP5829372B2 (ja) | 2015-12-09 |
Family
ID=37308324
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008510224A Active JP5829372B2 (ja) | 2005-05-02 | 2006-05-02 | 神経代謝性疾患のための遺伝子治療 |
| JP2013201138A Pending JP2014037418A (ja) | 2005-05-02 | 2013-09-27 | 神経代謝性疾患のための遺伝子治療 |
| JP2015197051A Active JP6338560B2 (ja) | 2005-05-02 | 2015-10-02 | 神経代謝性疾患のための遺伝子治療 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013201138A Pending JP2014037418A (ja) | 2005-05-02 | 2013-09-27 | 神経代謝性疾患のための遺伝子治療 |
| JP2015197051A Active JP6338560B2 (ja) | 2005-05-02 | 2015-10-02 | 神経代謝性疾患のための遺伝子治療 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10632213B2 (OSRAM) |
| EP (4) | EP3058959B1 (OSRAM) |
| JP (3) | JP5829372B2 (OSRAM) |
| CN (4) | CN101212988A (OSRAM) |
| AT (1) | ATE525092T1 (OSRAM) |
| AU (1) | AU2006243776A1 (OSRAM) |
| BR (1) | BRPI0611379A2 (OSRAM) |
| CA (2) | CA2998603C (OSRAM) |
| ES (1) | ES2887076T3 (OSRAM) |
| IL (2) | IL187078A (OSRAM) |
| PL (4) | PL3520823T3 (OSRAM) |
| PT (4) | PT1879624E (OSRAM) |
| WO (1) | WO2006119458A1 (OSRAM) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3302529B2 (ja) | 1995-04-28 | 2002-07-15 | 株式会社クボタ | ポンプ吸水槽の整流装置 |
| EP1879623B1 (en) * | 2005-05-02 | 2012-10-03 | Genzyme Corporation | Gene therapy for spinal cord disorders |
| BRPI0611379A2 (pt) | 2005-05-02 | 2010-08-31 | Genzyme Corp | terapia genética para distúrbios neurometabólicos |
| MX364444B (es) | 2006-06-07 | 2019-04-26 | Genzyme Corp | Terapia génica para esclerosis lateral amiotrófica y otros trastornos de la médula espinal. |
| PT3252161T (pt) * | 2007-06-06 | 2022-02-01 | Genzyme Corp | Terapia genética para doenças do armazenamento lisossomal |
| EP2687609B1 (en) | 2008-11-10 | 2017-01-04 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Method for treating solid tumor |
| EP3988660B1 (en) | 2009-05-02 | 2025-05-14 | Genzyme Corporation | Gene therapy for neurodegenerative disorders |
| US9150926B2 (en) | 2010-12-06 | 2015-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Diagnosis and treatment of adrenocortical tumors using human microRNA-483 |
| WO2012145646A1 (en) * | 2011-04-20 | 2012-10-26 | Miguel Sena-Esteves | Methods for the treatment of tay-sachs disease, sandhoff disease, and gmi-gangliosidosis |
| EP3151866B1 (en) | 2014-06-09 | 2023-03-08 | Voyager Therapeutics, Inc. | Chimeric capsids |
| KR20170096998A (ko) | 2014-11-05 | 2017-08-25 | 보이저 테라퓨틱스, 인크. | 파킨슨병의 치료를 위한 aadc 폴리뉴클레오티드 |
| WO2016077687A1 (en) | 2014-11-14 | 2016-05-19 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| WO2016077689A1 (en) | 2014-11-14 | 2016-05-19 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
| US11319555B2 (en) | 2014-11-20 | 2022-05-03 | Duke University | Compositions, systems and methods for cell therapy |
| WO2016094783A1 (en) | 2014-12-12 | 2016-06-16 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scaav |
| CR20170407A (es) | 2015-02-10 | 2017-11-14 | Genzyme Corp | Mejora del suministro de partículas virales al cuerpo estriado y al córtex |
| WO2016150403A1 (en) * | 2015-03-26 | 2016-09-29 | Fujian Tiantai Medical Technology Co. Ltd | Method of diagnosis or treatment of neurological disorders with p75ecd and/or p75 |
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| WO2016196507A1 (en) * | 2015-05-29 | 2016-12-08 | University Of Iowa Research Foundation | Methods of delivery of transgenes for treating brain diseases |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| EP3448987A4 (en) | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| CA3024448C (en) | 2016-05-18 | 2025-09-09 | Voyager Therapeutics, Inc. | MODULATING POLYNUCLEOTIDES |
| BR112018073472A2 (pt) | 2016-05-18 | 2019-08-27 | Voyager Therapeutics Inc | composições e métodos de tratamento da doença de huntington |
| JP2019531787A (ja) | 2016-08-30 | 2019-11-07 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 生物医学的ターゲティング及びデリバリーの方法並びにそれを実行するための装置及びシステム |
| JOP20190200A1 (ar) | 2017-02-28 | 2019-08-27 | Univ Pennsylvania | تركيبات نافعة في معالجة ضمور العضل النخاعي |
| SG11201909868YA (en) | 2017-05-05 | 2019-11-28 | Voyager Therapeutics Inc | Compositions and methods of treating huntington's disease |
| WO2018204786A1 (en) | 2017-05-05 | 2018-11-08 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| BR112019025888A2 (pt) | 2017-06-07 | 2020-06-30 | Regeneron Pharmaceuticals, Inc. | polinucleotídeo que codifica uma proteína terapêutica multidomínio, vetor de terapia gênica, proteína terapêutica multidomínio recombinante, método de expressão, métodos para reduzir o acúmulo de glicogênio em um tecido em um paciente em necessidade, para reduzir o acúmulo de glicogênio em um tecido em um paciente em necessidade epara tratar a deficiência enzimática em um paciente em necessidade e/ou tolerar o paciente à enzima para a qual é deficiente, anticorpo anti-cd63 ou fragmento de ligação a antígeno, e, composição farmacêutica |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| CA3070087A1 (en) | 2017-07-17 | 2019-01-24 | Voyager Therapeutics, Inc. | Trajectory array guide system |
| EP3662060A2 (en) | 2017-08-03 | 2020-06-10 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
| CA3075656A1 (en) | 2017-09-29 | 2019-04-04 | Voyager Therapeutics, Inc. | Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery |
| EP4454654A3 (en) | 2017-10-16 | 2025-02-19 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
| WO2019079240A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
| JP7779653B2 (ja) | 2018-02-07 | 2025-12-03 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 治療用タンパク質送達のための方法および組成物 |
| JP2021523914A (ja) | 2018-05-15 | 2021-09-09 | ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | パーキンソン病を治療するための組成物および方法 |
| MY206284A (en) | 2018-05-17 | 2024-12-06 | Regeneron Pharma | Anti-cd63 antibodies, conjugates, and uses thereof |
| JP7528066B2 (ja) | 2018-09-28 | 2024-08-05 | ボイジャー セラピューティクス インコーポレイテッド | 操作されたプロモータを有するフラタキシン発現コンストラクトおよびその使用方法 |
| KR20240126916A (ko) * | 2023-02-14 | 2024-08-22 | 경북대학교 산학협력단 | Asm 단백질 또는 이의 단편을 포함하는 퇴행성 신경질환 또는 우울증 예방 또는 치료용 조성물 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8303626D0 (sv) | 1983-06-23 | 1983-06-23 | Kabigen Ab | A recombinant plasmid a transformant microorganism, a polydoxyrebonucleotide segment, a process for producing a biologically active protein, and the protein thus produced |
| US5672344A (en) | 1987-12-30 | 1997-09-30 | The Regents Of The University Of Michigan | Viral-mediated gene transfer system |
| US5773278A (en) | 1991-05-03 | 1998-06-30 | Mount Sinai Medical Center | Acid sphingomyelinase gene |
| JP3532566B2 (ja) | 1993-06-24 | 2004-05-31 | エル． グラハム，フランク | 遺伝子治療のためのアデノウイルスベクター |
| DE69435223D1 (de) | 1993-10-25 | 2009-09-03 | Canji Inc | Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung |
| JPH09509564A (ja) | 1993-11-09 | 1997-09-30 | ターゲテッド ジェネティックス コーポレイション | 高力価組換えａａｖベクターの生成 |
| US7252989B1 (en) | 1994-04-04 | 2007-08-07 | Board Of Regents, The University Of Texas System | Adenovirus supervector system |
| EP0755454B1 (en) | 1994-04-13 | 2008-02-13 | The Rockefeller University | Aav-mediated delivery of dna to cells of the nervous system |
| AU1525797A (en) | 1996-04-22 | 1997-11-12 | Medtronic, Inc. | Two-stage angled venous cannula |
| US6544785B1 (en) | 1998-09-14 | 2003-04-08 | Mount Sinai School Of Medicine Of New York University | Helper-free rescue of recombinant negative strand RNA viruses |
| WO2001036603A2 (en) * | 1999-11-17 | 2001-05-25 | Avigen, Inc. | Recombinant adeno-associated virus virions for the treatment of lysosomal disorders |
| US20030165481A1 (en) * | 2000-02-24 | 2003-09-04 | Hersh Louis B. | Amyloid peptide inactivating enzyme to treat Alzheimer's disease |
| CA2423082A1 (en) | 2000-09-18 | 2002-03-28 | Genzyme Corporation | Expression vectors containing hybrid ubiquitin promoters |
| US20030050273A1 (en) * | 2001-08-29 | 2003-03-13 | Keiya Ozawa | Compositions and methods for treating neurodegenerative diseases |
| US7232670B2 (en) * | 2001-09-28 | 2007-06-19 | St. Jude Children's Research Hospital | Targeting proteins to cells expressing mannose receptors via expression in insect cells |
| JP4810062B2 (ja) | 2001-12-17 | 2011-11-09 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | アデノ随伴ウイルス（ａａｖ）血清型８の配列 |
| AU2002364221B2 (en) | 2001-12-21 | 2008-07-10 | The Salk Institute For Biological Studies | Targeted retrograde gene delivery to motor neurons |
| US6998118B2 (en) | 2001-12-21 | 2006-02-14 | The Salk Institute For Biological Studies | Targeted retrograde gene delivery for neuronal protection |
| US7807618B2 (en) * | 2002-05-20 | 2010-10-05 | The Board Of Regents Of The University Of Texas System | Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone and other tissues |
| PT1620133E (pt) * | 2003-05-01 | 2016-03-31 | Genzyme Corp | Terapia genética para distúrbios neurometabólicos |
| US20040258666A1 (en) * | 2003-05-01 | 2004-12-23 | Passini Marco A. | Gene therapy for neurometabolic disorders |
| US7740168B2 (en) | 2003-08-18 | 2010-06-22 | Visa U.S.A. Inc. | Method and system for generating a dynamic verification value |
| AU2003272868A1 (en) | 2003-10-15 | 2005-04-27 | Agtc Gene Technology Company Ltd. | Method for large-scale production, isolation, purification and the uses of multi-type recombinant adeno-associated virus vectors |
| EP1716870A1 (en) | 2005-04-29 | 2006-11-02 | Bracco Imaging S.p.A. | MRI contrast agents endowed with concentration independent responsiveness |
| EP1879623B1 (en) | 2005-05-02 | 2012-10-03 | Genzyme Corporation | Gene therapy for spinal cord disorders |
| BRPI0611379A2 (pt) | 2005-05-02 | 2010-08-31 | Genzyme Corp | terapia genética para distúrbios neurometabólicos |
| LT1986661T (lt) | 2006-02-08 | 2018-12-10 | Genzyme Corporation | Nimano-piko a tipo ligos genų terapija |
| RU2638802C2 (ru) | 2011-05-16 | 2017-12-15 | Джензим Корпорейшн | Применение антагонистов cxcr4 |
| TWI821227B (zh) | 2017-12-22 | 2023-11-11 | 美商健臻公司 | 胺甲喋呤誘發的免疫耐受性之生物標記 |
-
2006
- 2006-05-02 BR BRPI0611379-6A patent/BRPI0611379A2/pt not_active Application Discontinuation
- 2006-05-02 PL PL19153520T patent/PL3520823T3/pl unknown
- 2006-05-02 EP EP16162716.1A patent/EP3058959B1/en active Active
- 2006-05-02 CN CNA2006800237754A patent/CN101212988A/zh active Pending
- 2006-05-02 EP EP11169633.2A patent/EP2420256B1/en active Active
- 2006-05-02 AU AU2006243776A patent/AU2006243776A1/en not_active Abandoned
- 2006-05-02 PT PT06759081T patent/PT1879624E/pt unknown
- 2006-05-02 PL PL16162716T patent/PL3058959T3/pl unknown
- 2006-05-02 EP EP19153520.2A patent/EP3520823B1/en active Active
- 2006-05-02 ES ES19153520T patent/ES2887076T3/es active Active
- 2006-05-02 PT PT19153520T patent/PT3520823T/pt unknown
- 2006-05-02 PT PT16162716T patent/PT3058959T/pt unknown
- 2006-05-02 JP JP2008510224A patent/JP5829372B2/ja active Active
- 2006-05-02 EP EP06759081A patent/EP1879624B1/en active Active
- 2006-05-02 PT PT111696332T patent/PT2420256T/pt unknown
- 2006-05-02 AT AT06759081T patent/ATE525092T1/de not_active IP Right Cessation
- 2006-05-02 PL PL06759081T patent/PL1879624T3/pl unknown
- 2006-05-02 CA CA2998603A patent/CA2998603C/en active Active
- 2006-05-02 PL PL11169633.2T patent/PL2420256T3/pl unknown
- 2006-05-02 CN CN201611031204.7A patent/CN107007842A/zh active Pending
- 2006-05-02 CA CA2607173A patent/CA2607173C/en active Active
- 2006-05-02 CN CN201410483749.6A patent/CN104306986A/zh active Pending
- 2006-05-02 WO PCT/US2006/017242 patent/WO2006119458A1/en not_active Ceased
- 2006-05-02 CN CN201710506914.9A patent/CN107362371A/zh active Pending
-
2007
- 2007-11-01 IL IL187078A patent/IL187078A/en not_active IP Right Cessation
- 2007-11-02 US US11/934,325 patent/US10632213B2/en active Active
-
2013
- 2013-09-27 JP JP2013201138A patent/JP2014037418A/ja active Pending
-
2015
- 2015-06-03 IL IL239167A patent/IL239167A0/en unknown
- 2015-10-02 JP JP2015197051A patent/JP6338560B2/ja active Active
-
2020
- 2020-03-03 US US16/808,206 patent/US11957765B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008540445A5 (OSRAM) | ||
| Ling et al. | AAV-based in vivo gene therapy for neurological disorders | |
| Liu et al. | Crossing the blood-brain barrier with AAV vectors | |
| US11957765B2 (en) | Gene therapy for neurometabolic disorders | |
| Zhang et al. | Several rAAV vectors efficiently cross the blood–brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system | |
| JP2009526067A5 (OSRAM) | ||
| Murlidharan et al. | Biology of adeno-associated viral vectors in the central nervous system | |
| Cheng et al. | Gene therapy progress and prospects: gene therapy of lysosomal storage disorders | |
| JP6312771B2 (ja) | 神経代謝性疾患についての遺伝子治療 | |
| EP3498851B1 (en) | Cns gene delivery using peripheral administration of aav vectors | |
| TWI547288B (zh) | 用於治療疾病之載體及序列 | |
| Miyake et al. | Global gene transfer into the CNS across the BBB after neonatal systemic delivery of single-stranded AAV vectors | |
| JP2016503405A5 (OSRAM) | ||
| EA036394B1 (ru) | Псевдотипированный вектор на основе аденоассоциированного вируса aav-5 для генной терапии неврологических заболеваний | |
| Hironaka et al. | Enzyme replacement in the CSF to treat metachromatic leukodystrophy in mouse model using single intracerebroventricular injection of self-complementary AAV1 vector | |
| WO2005120581A2 (en) | Gene therapy for neurometabolic disorders | |
| Ruzo et al. | Liver production of sulfamidase reverses peripheral and ameliorates CNS pathology in mucopolysaccharidosis IIIA mice | |
| Gomez Limia et al. | Emerging perspectives on gene therapy delivery for neurodegenerative and neuromuscular disorders | |
| Hildinger et al. | Advances in AAV-mediated gene transfer for the treatment of inherited disorders | |
| Cardone | Prospects for gene therapy in inherited neurodegenerative diseases | |
| US20230277687A1 (en) | Viral particles for use in treating tauopathies such as alzheimer's diseases by gene therapy | |
| Miyake et al. | Gene delivery into the central nervous system (CNS) using AAV vectors | |
| Weismann | Let us know how access to this document benefits you. | |
| Murlidharan et al. | Gene Therapy of CNS Disorders Using Recombinant AAV Vectors | |
| Broekman | Discussion and conclusion |